TSHA Q2 2022 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$33M

Net Income

-$34M

EPS (Diluted)

$-0.85

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$41M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$142M

Total Liabilities

$110M

Stockholders' Equity

$33M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$33M	-$41M	+18.1%
Net Income	-$34M	-$41M	+16.7%